Safety of edaravone in real-world use: analysis based on FDA adverse event reporting system
This study confirmed previously reported adverse events and identified several new ones associated with edaravone. These findings provide valuable insights for optimizing ALS patient management and highlight the need for further research into the mechanisms of these adverse reactions.
Authors
- Tao Peng (ORCID: https://orcid.org/0000-0002-2898-7586)
- Detian Wan (ORCID: https://orcid.org/0009-0001-7427-2653)
- Yongmei Yan
- Yalong Kang
- Lan Huang (ORCID: https://orcid.org/0000-0001-9594-4722)
- Xiaxia Jin
- Nan Hu (ORCID: https://orcid.org/0000-0003-3509-0862)
- Yifan Yang (ORCID: https://orcid.org/0009-0008-3094-4914)
- Hui Zhang (ORCID: https://orcid.org/0000-0003-1520-2433)
Institutions
- The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine (CN)
- Guangxi University of Chinese Medicine (CN)
- Affiliated Hospital of Shaanxi University of Chinese Medicine (CN)
- China Academy of Chinese Medical Sciences (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1080/14740338.2025.2470874
- Primary Topic
- Pharmacy and Medical Practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00